Charles Schwab Investment Management Inc. Boosts Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Charles Schwab Investment Management Inc. raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 2,268,886 shares of the biopharmaceutical company's stock after purchasing an additional 90,195 shares during the period. Charles Schwab Investment Management Inc. owned 0.77% of Amicus Therapeutics worth $32,195,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of FOLD. Vontobel Holding Ltd. bought a new stake in shares of Amicus Therapeutics during the 4th quarter valued at about $1,173,000. Envestnet Asset Management Inc. boosted its position in Amicus Therapeutics by 170.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 393,728 shares of the biopharmaceutical company's stock valued at $4,788,000 after purchasing an additional 248,220 shares during the period. O Shaughnessy Asset Management LLC grew its stake in Amicus Therapeutics by 25.3% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company's stock worth $185,000 after buying an additional 3,082 shares during the last quarter. Vanguard Group Inc. increased its position in Amicus Therapeutics by 0.4% in the third quarter. Vanguard Group Inc. now owns 27,131,873 shares of the biopharmaceutical company's stock worth $329,924,000 after buying an additional 107,456 shares during the period. Finally, MPM Bioimpact LLC lifted its stake in Amicus Therapeutics by 38.7% in the third quarter. MPM Bioimpact LLC now owns 716,139 shares of the biopharmaceutical company's stock valued at $8,708,000 after buying an additional 200,000 shares during the last quarter.

Amicus Therapeutics Price Performance

Shares of FOLD traded down $0.19 during midday trading on Wednesday, reaching $9.72. The stock had a trading volume of 2,160,833 shares, compared to its average volume of 2,973,569. The company has a debt-to-equity ratio of 2.97, a current ratio of 3.03 and a quick ratio of 2.61. The company has a market capitalization of $2.88 billion, a P/E ratio of -20.29 and a beta of 0.80. The firm's 50 day moving average price is $10.78 and its 200-day moving average price is $11.89. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.04. The firm had revenue of $110.40 million for the quarter, compared to analysts' expectations of $111.19 million. Amicus Therapeutics had a negative net margin of 34.73% and a negative return on equity of 77.08%. Amicus Therapeutics's revenue for the quarter was up 27.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.18) earnings per share. On average, analysts forecast that Amicus Therapeutics, Inc. will post -0.19 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company's stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total transaction of $75,525.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at $8,928,605.78. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on FOLD shares. UBS Group dropped their price objective on shares of Amicus Therapeutics from $20.00 to $19.00 and set a "buy" rating on the stock in a report on Friday, May 10th. Guggenheim raised Amicus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target on the stock in a report on Tuesday, May 14th. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a report on Friday, May 10th. Bank of America cut their target price on Amicus Therapeutics from $14.00 to $13.00 and set a "buy" rating on the stock in a research note on Friday, May 10th. Finally, Morgan Stanley decreased their price target on Amicus Therapeutics from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Friday, May 10th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Amicus Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $17.50.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.